S&P 500   3,266.36 (+0.61%)
DOW   26,913.38 (+0.37%)
QQQ   267.95 (+0.96%)
AAPL   110.17 (+1.80%)
MSFT   206.05 (+1.41%)
FB   250.29 (+0.30%)
GOOGL   1,424.10 (+0.09%)
AMZN   3,040.11 (+0.67%)
TSLA   402.17 (+3.71%)
NVDA   504.79 (+2.20%)
BABA   267.78 (-0.72%)
CGC   13.92 (-2.45%)
GE   6.04 (-0.33%)
MU   48.31 (-2.34%)
AMD   76.59 (+1.02%)
T   27.83 (-0.75%)
F   6.53 (-1.95%)
ACB   4.99 (-4.04%)
GILD   61.91 (-0.55%)
NFLX   476.35 (+0.69%)
DIS   122.45 (-0.03%)
BAC   23.28 (-0.26%)
BA   150.58 (+3.10%)
S&P 500   3,266.36 (+0.61%)
DOW   26,913.38 (+0.37%)
QQQ   267.95 (+0.96%)
AAPL   110.17 (+1.80%)
MSFT   206.05 (+1.41%)
FB   250.29 (+0.30%)
GOOGL   1,424.10 (+0.09%)
AMZN   3,040.11 (+0.67%)
TSLA   402.17 (+3.71%)
NVDA   504.79 (+2.20%)
BABA   267.78 (-0.72%)
CGC   13.92 (-2.45%)
GE   6.04 (-0.33%)
MU   48.31 (-2.34%)
AMD   76.59 (+1.02%)
T   27.83 (-0.75%)
F   6.53 (-1.95%)
ACB   4.99 (-4.04%)
GILD   61.91 (-0.55%)
NFLX   476.35 (+0.69%)
DIS   122.45 (-0.03%)
BAC   23.28 (-0.26%)
BA   150.58 (+3.10%)
S&P 500   3,266.36 (+0.61%)
DOW   26,913.38 (+0.37%)
QQQ   267.95 (+0.96%)
AAPL   110.17 (+1.80%)
MSFT   206.05 (+1.41%)
FB   250.29 (+0.30%)
GOOGL   1,424.10 (+0.09%)
AMZN   3,040.11 (+0.67%)
TSLA   402.17 (+3.71%)
NVDA   504.79 (+2.20%)
BABA   267.78 (-0.72%)
CGC   13.92 (-2.45%)
GE   6.04 (-0.33%)
MU   48.31 (-2.34%)
AMD   76.59 (+1.02%)
T   27.83 (-0.75%)
F   6.53 (-1.95%)
ACB   4.99 (-4.04%)
GILD   61.91 (-0.55%)
NFLX   476.35 (+0.69%)
DIS   122.45 (-0.03%)
BAC   23.28 (-0.26%)
BA   150.58 (+3.10%)
S&P 500   3,266.36 (+0.61%)
DOW   26,913.38 (+0.37%)
QQQ   267.95 (+0.96%)
AAPL   110.17 (+1.80%)
MSFT   206.05 (+1.41%)
FB   250.29 (+0.30%)
GOOGL   1,424.10 (+0.09%)
AMZN   3,040.11 (+0.67%)
TSLA   402.17 (+3.71%)
NVDA   504.79 (+2.20%)
BABA   267.78 (-0.72%)
CGC   13.92 (-2.45%)
GE   6.04 (-0.33%)
MU   48.31 (-2.34%)
AMD   76.59 (+1.02%)
T   27.83 (-0.75%)
F   6.53 (-1.95%)
ACB   4.99 (-4.04%)
GILD   61.91 (-0.55%)
NFLX   476.35 (+0.69%)
DIS   122.45 (-0.03%)
BAC   23.28 (-0.26%)
BA   150.58 (+3.10%)
Log in
NASDAQ:FRLN

Freeline Therapeutics Stock Forecast, Price & News

$16.40
-0.11 (-0.67 %)
(As of 09/24/2020 12:00 AM ET)
Add
Compare
Today's Range
$16.37
Now: $16.40
$16.93
50-Day Range N/A
52-Week Range
$15.25
Now: $16.40
$21.69
Volume22,419 shs
Average Volume125,970 shs
Market Capitalization$425.10 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Freeline Therapeutics Holdings plc operates as a clinical-stage systemic adeno-associated virus (AAV)-based gene therapy company. Its advanced product candidate is FLT180a, a gene therapy product candidate that is being evaluated in a Phase 1/2 dose-finding clinical trials in adult males for the treatment of patients with moderate or severe hemophilia B. The company's products also include FLT190, which is in dose-escalating Phase 1/2 clinical trials for the treatment of Fabry disease; FLT201, a liver-directed gene therapy product candidate to treat type 1 Gaucher disease; and FLT210, a liver-directed gene therapy product candidate for the treatment of hemophilia A. In addition, it has research programs in various indications for systemic gene therapy. The company was founded in 2015 and is headquartered in Stevenage, the United Kingdom.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.13 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:FRLN
CUSIPN/A
CIKN/A
Phone44-14-3890-6870

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees200
Market Cap$425.10 million
Next Earnings DateN/A
OptionableNot Optionable
$16.40
-0.11 (-0.67 %)
(As of 09/24/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive FRLN News and Ratings via Email

Sign-up to receive the latest news and ratings for FRLN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Freeline Therapeutics (NASDAQ:FRLN) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Freeline Therapeutics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Freeline Therapeutics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Freeline Therapeutics
.

Who are some of Freeline Therapeutics' key competitors?

What other stocks do shareholders of Freeline Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Freeline Therapeutics investors own include Adobe (ADBE), CVS Health (CVS), Old Dominion Freight Line (ODFL), Shopify (SHOP), Zoom Video Communications (ZM), Zymeworks (ZYME), AbbVie (ABBV), American Airlines Group (AAL), Abbott Laboratories (ABT) and Advanced Micro Devices (AMD).

Who are Freeline Therapeutics' key executives?

Freeline Therapeutics' management team includes the following people:
  • Ms. Theresa Marie Heggie, Chief Exec. Officer (Age 60)
  • Mr. Brian M. Silver, CFO & Head of Corp. Devel. (Age 51)
  • Dr. Amit Nathwani M.D., Ph.D., Chief Scientific Officer and Director (Age 60)
  • Dr. Jan Thirkettle Ph.D., Chief Devel. Officer (Age 48)
  • Dr. Gerard Short, Head of Clinical and Regulatory

When did Freeline Therapeutics IPO?

(FRLN) raised $126 million in an initial public offering (IPO) on Friday, August 7th 2020. The company issued 7,400,000 shares at $16.00-$18.00 per share. J.P. Morgan, Morgan Stanley and Evercore ISI served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is Freeline Therapeutics' stock symbol?

Freeline Therapeutics trades on the NASDAQ under the ticker symbol "FRLN."

When did Freeline Therapeutics' quiet period expire?

Freeline Therapeutics' quiet period expired on Wednesday, September 16th. Freeline Therapeutics had issued 8,823,529 shares in its IPO on August 7th. The total size of the offering was $158,823,522 based on an initial share price of $18.00. During Freeline Therapeutics' quiet period, underwriters and any insiders that worked on the IPO were prevented from issuing any research reports for the company because of regulations issued by the Securities and Exchange Commission. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company.

How do I buy shares of Freeline Therapeutics?

Shares of FRLN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Freeline Therapeutics' stock price today?

One share of FRLN stock can currently be purchased for approximately $16.40.

How big of a company is Freeline Therapeutics?

Freeline Therapeutics has a market capitalization of $425.10 million. Freeline Therapeutics employs 200 workers across the globe.

What is Freeline Therapeutics' official website?

The official website for Freeline Therapeutics is www.freeline.life.

How can I contact Freeline Therapeutics?

Freeline Therapeutics' mailing address is STEVENAGE BIOSCIENCE CATALYST GUNNELS WOOD ROAD STEVENAGE, HERTFORDSHIRE X0, SG12FX. The company can be reached via phone at 44-14-3890-6870 or via email at [email protected]

This page was last updated on 9/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.